REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD)

• Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation/perfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy.

• Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology.

• Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units

Locations
Other Locations
Mexico
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
RECRUITING
Mexico City
Contact Information
Primary
Jose Luis Hernandez Oropeza, PhD
elinternista@hotmail.com
+52 55 5487 0900
Backup
Jose de Jesus Rodriguez Andoney, M.Sc.
andoneyjjr@hotmail.com
+52 55 5487 0900
Time Frame
Start Date: 2022-12-15
Estimated Completion Date: 2027-12
Participants
Target number of participants: 170
Treatments
Pulmonary Arterial Hypertension (Group I)
Group I Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
Pulmonary Arterial Hypertension (Group IV)
Group IV Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
Related Therapeutic Areas
Sponsors
Leads: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

This content was sourced from clinicaltrials.gov